OWL-LABS
23.6.2021 01:03:07 CEST | Business Wire | Press release
Research conducted by Owl Labs , which polled 2000 business leaders* based in the UK, Germany, France, and the Nordics** shows that just 11% of business leaders expect their employees to return to the office full-time, indicating a more permanent shift to hybrid working. What’s more, the majority of European organisations (92%) are keen to explore progressive policies post-pandemic including introducing working from anywhere (42%), core working hours (39%), a four-day week (39%), and unlimited holiday (22%). When considering why employers are permanently moving to a more flexible work model, profitability plays an important role. Close to two-thirds (62%) of European business leaders reported that hybrid working makes companies more profitable with Enterprise businesses (1000+ employees) the most likely to think so (73%) versus small and medium-sized companies (55%).
As businesses continue to adapt to working in a Covid-19 environment, over a third (39%) of European business leaders anticipate that Covid-19 will continue to impact the running of their business for up to six months. French business leaders are the most optimistic with one in five (20%) believing Covid-19 would only impact the running of their office for the next three months or less. However, the majority believe that remote and hybrid working has positively impacted their business, with the majority stating it had impacted employee wellbeing (52%) and business costs (50%) positively.
With a growing desire to support employees' partial return-to-office, one in four EU organisations (24%) are now planning to enforce ‘vaccine passports’ and only allow those who have been vaccinated into the office. Germany is the most cautious with 31% of business leaders insisting on Covid-19 vaccines, while 23% of business leaders in the UK, 21% in the Nordics and 19% in France intend to enforce vaccines. Additionally, over a third (38%) of EU business leaders are considering providing onsite Covid-19 testing facilities to encourage employees to return to work, with French and German organisations most likely to provide onsite testing facilities at 42% and 43% respectively.
European organisations are already planning ahead to a post-pandemic work environment, with the majority of business leaders (63%) aiming to maintain the same amount of office space, even with the rise of hybrid work. Just 11% are planning to get rid of their offices entirely (rising to 14% in the Nordics). When it comes to hiring, one-third of EU organisations (32%) plan to hire employees who can work remotely, based on skill, rather than their proximity to an office. In a move that may not be welcomed by employees, 29% of business leaders plan to use productivity apps to monitor activity of remote employees. This rises steeply in Germany, where 37% of business leaders plan on utilising productivity and activity monitoring of remote employees, compared to just 22% of Nordic business leaders.
As businesses move to hybrid and flexible working, technology plays a crucial role in enabling this shift. As a result, the majority (93%) of European organisations are putting workplace policies and infrastructure in place to prepare for a post-pandemic workplace. This includes nearly half (42%) of European businesses investing in new tech and solutions to support a hybrid workforce. The UK leads the tech charge with 43% investing in communications tools (such as Slack, Zoom, and Meeting Owl conference cameras) compared to 28% in the Nordics, 36% in France and 38% in Germany. The primary activities companies are carrying out to prepare their workplaces now and post-pandemic are:
○ Investing in communication tools and technology (Slack, Zoom, conference cameras, Meeting Owls, etc.) (36%)
○ Continued social-distancing measures for employees in the office (35%)
○ Providing at-home and in-office equipment for employees so they can easily work from both locations (33%)
Frank Weishaupt, CEO of Owl Labs says, “It’s encouraging to see business leaders across Europe embrace hybrid work post-pandemic. As organisations have adapted to working remotely, they’ve seen the benefits. The ability to hire remote teams from anywhere, leverage new technologies whilst saving on costs. We know that technology will continue to play a key role in supporting this permanent shift to hybrid work, and businesses that will be successful will create the infrastructure and workplace policies that enable their employees to maintain high levels of creativity and collaboration, wherever they dial-in from.”
---ends---
Methodology:
* Business Leaders refer to C-suite executives, heads of departments, HR managers and general managers
**The Nordics refers to Sweden, Finland, Norway & Denmark
About Owl Labs
Owl Labs is a collaborative technology company dedicated to creating a better workplace and learning experience for today's hybrid workforce and virtual classroom. The company’s flagship product, the award-winning Meeting Owl Pro , features a wifi-enabled, portable 360° camera, mic, and speaker with proprietary AI technology that automatically focuses on who is speaking using audio and visual cues. The company is a recipient of TIME’s Best Inventions of 2020 and is dedicated to providing collaborative and productivity solutions for organizations to stay connected to their remote employees and educators to stay connected to their remote students, regardless of location. Learn more at www.owllabs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
